PBI22 Rethinking the Health-Economic Evaluation Framework for GENE Therapies: The Betibeglogene Autotemcel (BETI-CEL) Case in Î’-Thalassemia
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.100
https://www.valueinhealthjournal.com/article/S1098-3015(20)32356-1/fulltext
Section Title :
Section Order :
10071
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32356-1&doi=10.1016/j.jval.2020.08.100